AJANTPHARM

💼 Market and Analyst Sentiment

Revenue: Around ₹1,300 crore, up nearly 14% year on year. Net Profit: Approximately ₹255 crore, a 4% increase YoY. EBITDA Margin: Close to 27%, indicating operational strength. Cash Flow: Free cash flow conversion above 80%, showing efficient operations. Forex Impact: Margins were slightly affected by a ₹25 crore forex loss due to currency fluctuations. 🏛️ Corporate Updates The company’s next board meeting is scheduled for early November 2025 to approve Q2 FY26 financial results. Ajanta Pharma has published its annual sustainability report for FY25, aligned with global GRI reporting standards. Promoter shareholding has shown a small decline in recent years, but overall promoter confidence remains strong. 💼 Market and Analyst Sentiment Brokerage Views: Some brokerages maintain a Buy rating with target prices around ₹3,000–₹3,200. Others hold a Neutral or Reduce stance due to rich valuations. Mutual Fund Activity: Certain mid-cap funds have slightly reduced holdings, showing cautious sentiment in the sector. Technical View: A recent moving average crossover indicated short-term bearishness, though sector strength may offer support.